Paul Griffin
Director of Infectious Diseases at Mater Health Services
ABOUT
An Infectious Diseases Physician and Microbiologist, Dr Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013. In addition Dr Griffin continues appointments as Principal Investigator at Q-Pharm, as Visiting Scientist/Honorary Research Fellow at Mater Medical Research Institute and Queensland Institute of Medical Research, and also as Senior Lecturer at the University of Queensland.
Dr Paul Griffin's primary research interests include clinical trials in the field of infectious diseases particularly malaria human challenge and transmission blocking studies, as well as the detection of antibiotic resistance particularly VRE by mass spectrometry in the clinical microbiology laboratory.
EVENTS
Journal Articles
Evans, Thomas G, Bussey, Louise, Eagling-Vose, Elizabeth, Rutkowski, Kathryn, Ellis, Chris, Argent, Chris, Griffin, Paul, Kim, Joshua, Thackwray, Susan, Shakib, Sepehr, Doughty, Julia, Gillies, John, Wu, Jian, Druce, Julian, Pryor, Melinda and Gilbert, Sarah (2022). Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. The Lancet Infectious Diseases, 22 (6), 857-866. doi: 10.1016/S1473-3099(21)00702-7
Chughlay, M. Farouk, Barnes, Karen I., El Gaaloul, Myriam, Abla, Nada, Möhrle, Jörg J., Griffin, Paul, van Giersbergen, Paul, Reuter, Stephanie E., Schultz, Hayley B., Kress, Anita, Tapley, Peter, Webster, Rebecca A., Wells, Timothy, McCarthy, James S., Barber, Bridget E., Marquart, Louise, Boyle, Michelle J., Engwerda, Christian R. and Chalon, Stephan (2022). Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered Ruxolitinib and Artemether-Lumefantrine in healthy adults. Antimicrobial Agents and Chemotherapy, 66 (1) e01584-21, e0158421. doi: 10.1128/AAC.01584-21
Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine
Webster, Rebecca, Sekuloski, Silvana, Odedra, Anand, Woolley, Stephen, Jennings, Helen, Amante, Fiona, Trenholme, Katharine R., Healer, Julie, Cowman, Alan F., Eriksson, Emily M., Sathe, Priyanka, Penington, Jocelyn, Blanch, Adam J., Dixon, Matthew W. A., Tilley, Leann, Duffy, Michael F., Craig, Alister, Storm, Janet, Chan, Jo-Anne, Evans, Krystal, Papenfuss, Anthony T., Schofield, Louis, Griffin, Paul, Barber, Bridget E., Andrew, Dean, Boyle, Michelle J., de Labastida Rivera, Fabian, Engwerda, Christian and McCarthy, James S. (2021). Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Medicine, 19 (1) 293, 293. doi: 10.1186/s12916-021-02150-x